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Open Forum Infectious Diseases
MAJOR ARTICLE

Forgiveness of Dolutegravir-Based Triple Therapy
Compared With Older Antiretroviral Regimens:
A Prospective Multicenter Cohort of Adherence Patterns
and HIV-RNA Replication
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Background. For many people with HIV (PWH), taking antiretroviral therapy (ARV) every day is difficult.
Methods. Average adherence (Av-Adh) and log-transformed treatment interruption (TI) to ARV were prospectively measured over
6 months using electronic drug monitoring (EDM) in several cohorts of PWH. Multivariate linear regression models including baseline
confounders explored the influence of EDM-defined adherence (R2) on 6-month log10 HIV-RNA. Multivariate logistic regression models
were used to compare the risk of HIV-RNA detection (VR) within subgroups stratified by lower (≤95%) and higher (>95%) Av-Adh.
Results. Three hundred ninety-nine PWH were analyzed with different ARVs: dolutegravir (n = 102), raltegravir (n = 90), boosted PI
(bPI; n = 107), and NNRTI (n = 100). In the dolutegravir group, the influence of adherence pattern measures on R2 for HIV-RNA levels was
marginal (+2%). Av-Adh, TI, and Av-Adh × TI increased the R2 for HIV-RNA levels by 54% and 40% in the raltegravir and bPI treatment
groups, respectively. TI increased the R2 for HIV-RNA levels by 36% in the NNRTI treatment group. Compared with the dolutegravirbased regimen, the risk of VR was significantly increased for raltegravir (adjusted odds ratio [aOR], 45.6; 95% CI, 4.5–462.1; P = .001),
NNRTIs (aOR, 24.8; 95% CI, 2.7–228.4; P = .005), and bPIs (aOR, 28.3; 95% CI, 3.4–239.4; P = .002) in PWH with Av-Adh ≤95%. Among
PWH with >95% Av-Adh, there were no significant differences in the risk of VR among the different ARVs.
Conclusions. These findings support the concept that dolutegravir in combination with 2 other active ARVs achieves greater
virological suppression than older ARVs, including raltegravir, NNRTI, and bPI, among PWH with lower adherence.
Keywords. adherence; dolutegravir; PWH; missed doses.
Suboptimal adherence to antiretroviral therapy can result in
insufficient viral suppression [1,2] and promotes the emergence of drug-resistant viral strains [3]. A landmark study with
unboosted protease inhibitor antiretrovirals (ARVs) proposed
that >95% adherence was required to achieve and maintain virological suppression, which led to the concept that an undetectable HIV viral load (VL) was equivalent to full adherence
[1]. Modern antiretroviral therapies with once-daily dosing and
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low pill burden improved the level of adherence compared with
more complex regimens [4,5]. Simpler regimens have improved
adherence [4,6], and potent regimens with more favorable pharmacokinetic profiles have allowed more forgiveness with regard
to missed doses. Studies investigating non-nucleoside reverse
transcriptase inhibitors (NNRTI), boosted protease inhibitors
(bPIs), and integrase strand-transfer inhibitors (INSTI) as a part
of ARV drug combinations demonstrated that the lowest level
of ARV adherence required to sustain virological suppression
may be ~80% [7,8]. However, the methods used to measure adherence, such self-report and pharmacy refills, did not capture
treatment interruptions, another independent driver of virological failure [9] and resistance [10]. In addition, these studies
did not specifically investigate second-generation INSTI-based
ARV combinations, despite their being widely recommended.
Real-world studies of the “forgiveness” to missed doses
of ARV regimen are important, as they may help to predict
regimen durability and risk of resistance in a context where
Forgiveness of Dolutegravir • ofid • 1
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suboptimal adherence is probably common [11]. We hypothesized that the pharmacokinetic profile and genetic barrier provided by second-generation INSTIs, namely dolutegravir-based
ARV combinations, would allow a high rate of virological suppression at low to moderate adherence levels. Therefore, we
aimed to investigate the patterns of adherence to dolutegravir
associated with virological replication in comparison with older
third agents.
METHODS
Study Design and Participants
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Baseline characteristics including sociodemographic factors
and clinical characteristics were collected at baseline for the 4
groups: dolutegravir, raltegravir, bPIs, and NNRTIs. Patients
were asked to use electronic drug monitoring (EDM; Aardex,
Switzerland) devices to prospectively characterize their pattern of adherence to the third agent for 6 months. The same
monitoring strategy and devices were used for the 4 groups.
Other ARV pills (eg, backbone nucleos/tide reverse transcriptase inhibitors), if any, were not monitored. Two measures were
extracted from electronic dosing history for each participant:
(1) the average percent dose adherence corresponding to the
number of observed electronic pill cap opening events divided
by the expected events; (2) the log10-transformed duration of
the longest treatment interruption (in hours). EDM records
were read and reviewed at all study visits and allowed participants to add any doses taken when they knew they did not use
the device. Seventeen participants with no EDM events during
the 2 weeks prior to month 6 were excluded. This is because
nonpersistence to any short-acting antiretroviral drug is known
to be associated with virological replication in most situations.
Patient Consent Statement

The Institutional Review Board of the University of Caen, France
(which covers all French sites), and the Committee on Human
Subjects Research of the University of Lausanne, Switzerland,
approved all study procedures, and the participants provided
written informed consent.
Outcomes

The primary outcome was HIV-1 RNA in plasma, measured
using the test available in each center with a limit of detection
≤50 HIV-1 RNA copies/mL. We defined virological replication
as failure to suppress or sustain HIV-RNA to <50 copies/mL
at 6 months. A value of ≤50 was imputed to PWH who had a
lower limit of detection >50 copies/mL for 34 participants in the
NNRTI group and 56 participants in the bPI treatment group.
Emergence of resistance to dolutegravir and to raltegravir was
investigated by genotyping the integrase coding sequence of the
virus after the development of virological replication.
Statistical Analysis

Continuous variables were summarized as mean values, median values, SDs, and interquartile ranges (IQRs), depending
on their distributions. Dichotomous data were summarized
as numbers and proportions. Regarding baseline and follow-up characteristics, quantitative variables were compared
between ARV classes using an analysis of variance or KruskalWallis test, as appropriate, and qualitative variables were
compared using the Fisher exact test. In order to characterize
the adherence pattern associated with HIV-RNA replication,
we displayed a 3-dimensional scatter plot reporting the level
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We conducted an international multicenter prospective
cohort study of people with HIV (PWH) treated with a
dolutegravir-based regimen. The DOLUTECAPS study
took place in France and Switzerland between May 2015
and December 2018. The details of the inclusion criteria
are described in the clinical trial registration: https://
clinicaltrials.gov/ct2/show/NCT02878642. Briefly, adults
with HIV starting once- or twice-a-day dolutegravirbased regimens were included at the physician’s discretion.
Because we were interested in covering a large range of different pill-taking behaviors, the participation of PWH perceived by their treating physician to be at risk of suboptimal
adherence was encouraged. Subjects had a genotypic sensitivity score of ≥3, including dolutegravir. The genotypic
sensitivity score represents the total number of ARV drugs
in the regimen to which a patient’s HIV is susceptible (score
1), possibly susceptible (score 0.5), or resistant (score 0), according to version 30 of the ANRS AC-43 resistance group
algorithm (http://www.hivfrenchresistance.org/2019/tab6.
html). We did not include people using pillbox organizers
and those who were not responsible for taking their antiretroviral pills. Three groups of participants were defined:
antiretroviral-naïve individuals who initiated dolutegravir
(STARTING group), antiretroviral-experienced individuals who switched to dolutegravir for virological failure
(FAILING group), and antiretroviral-experienced individuals who switched to dolutegravir while HIV-RNA was
supressed (SWITCHING group). Dolutegravir combined
with abacavir/lamivudine as a single-tablet regimen and
multitablet regimens containing dolutegravir plus at least 2
other active ARVs were allowed.
Several centers from our group have incorporated the use
of EDM devices in routine practice. In addition, we previously investigated adherence–virological outcome relationships for older ARVs such as NNRTIs [12], bPIs [13,14], and
raltegravir [15]. We contrasted the DOLUTECAPS cohort findings with other antiretroviral therapies from our EDM database
(Supplementary Figure 1). All participants were followed prospectively with electronic adherence monitoring and an HIVRNA determination at 6 months as the primary outcome.

Data Collection and Adherence Pattern Measures

2.3.3 (Aardex Group, Sion, Switzerland), and SAS, version
9.4 (SAS Institute, Cary, NC, USA). All reported P values are
2-sided, with a P value of ≤.05 denoting statistical significance.

of log HIV-RNA (vertical z-axis) according to the average
adherence (horizontal x-axis) and log longest treatment interruption (horizontal y-axis). Because the original data did
not contain enough combinations of x, y, and z values to generate an empirically derived surface plot with <64% average
adherence, we censored these observations for data visualization. In addition, we used a smoothing spline interpolation method with λ = 0.1 as a trade-off between closeness
to the original data and smoothness. For each antiretroviral
group, we computed 3 different linear regression models—(i)
with average adherence (Model 1); (ii) with treatment interruption (Model 2); (iii) with average adherence, treatment
interruption, and the product (interaction) of average adherence × treatment interruption (Model 3)—as independent
covariables with the log HIV-RNA at 6 months as the dependent variable. These models were also adjusted for potential confounders (age, sex, baseline treatment scenarios [ie,
naïve, switch, or treatment failure], baseline HIV-RNA, and
CD4 cell count). The influence of the EDM-defined adherence pattern on 6-month HIV-RNA was assessed in 2 ways:
(i) by testing the slope of each adherence pattern parameter
coefficient to 0; (ii) by assessing the incremental R2 value (or
variance explained) for each model, compared with a model
without EDM adherence measurement (ie, including only
baseline factors).
The effect size of factors associated with the probability of virological detection (HIV-RNA >50 copies/mL) was estimated
by calculating odds ratios (ORs) and adjusted ORs using univariate and multivariate logistic regression models, respectively.
This analysis was performed in the overall cohort and in subgroups with higher (>95%) and lower (≤95%) average adherence [1]. Analyses were performed using PowerView, version

Baseline Characteristics

The baseline characteristics of the participants are shown in
Table 1. Seventy-two percent of the participants treated with
a dolutegravir-based regimen were men, and the mean age
was 47.7 years. Approximately one-quarter of the participants
treated with a dolutegravir-based regimen were treatmentnaïve at baseline. Fourty-seven (46%) PWH had a plasma HIVRNA <50 copies/mL at study entry. The median baseline CD4
cell count (IQR) was 494 (290–705), and the median baseline
plasma HIV-RNA level (IQR) was 2.1 (1.6–4.1) log10. The baseline characteristics from PWH treated with other third agents
are presented in Table 1. In the NNRTI-based group, the third
agent was nevirapine for 70 PWH, efavirenz for 12 PWH, and
rilpivirine for 18 PWH. In the boosted PI group, the third agent
was lopinavir for 54 PWH, atazanavir for 48 PWH, and other
boosted PI for 3 PWH.
HIV-RNA at Month 6

In the dolutegravir treatment group (Table 2), 8 PWH had
low levels of HIV-RNA replication: 5/24 (17%) in the failing
group (median [range] HIV-RNA, 132 [88–168] cp/mL), 2/26
(8%) in the starting group (HIV-RNA, 80 and 161 cp/mL),
and 1/46 (2%) in the switching group (HIV-RNA, 73 cp/mL).
Among these, 3/8 were amplified, and none demonstrated
a resistance mutation to the INSTI class. In the raltegravir
treatment group (Table 2), 18 PWH had HIV-RNA replication (median [range] HIV-RNA, 362 [57–51 300] copies/mL)

Baseline and Follow-up Characteristics by Antiretroviral Class

Variables

Dolutegravir-Based (n = 102)

Raltegravir-Based (n = 90)

NNRTI-Based (n = 100)

bPI-Based (n = 107)

P Value

Baseline characteristics
Age, mean (SD), y

47.7 (13.2)

46.2 (11.2)

46.8 (10.6)

Male, sex, No. (%)

73 (72)

65 (72)

86 (86)

CD4+ cells, median (IQR)

494 (290–705)

490 (309–709)

41.3 (7.6)
88 (82)

510 (383–723)

311 (229–450)

<.001
.028
<.001

Treatment groups, no. (%)/log HIV-1 RNA, median [IQR]
Switched treatment

47 (46)/1.7

69 (77)/1.7

Treatment-naïve

26 (26)/4.6 [4.0–5.0]

10 (11)/5.4 [3.6–5.5]

100 (100)/1.7
0 (0)/-

31 (29)/1.7
43 (40)/4.4 [3.8–5.1]

Failed treatment

29 (28)/3.2 [2.6–4.1]

11 (12)/4.6 [4.0–5.0]

0 (0)/-

33 (31)/2.8 [2.3–3.6]

TDF/FTC or TAF/FTC

22 (22)

49 (54)

22 (22)

56 (52)

ABC/3TC

47 (46)

6 (7)

38 (38)

10 (9)

<.001

Backbone

Other NRTI combination

8 (8)

12 (13)

40 (40)

13 (12)

Other class combination

25 (25)

23 (26)

0 (0)

28 (26)

<.001

Adherence follow-up
Average adherence, median (IQR)
Longest TI, median (IQR), d

96.0 (87.0–99.0)
2.1 (1.3–2.8)

97.0 (91.0–100.0)
1.5 (1.0–2.7)

96.0 (84.5–99.0)
1.3 (1.1–1.9)

95.3 (82.0–100.0)
2.0 (1.0–7.0)

.32
<.001

Abbreviations: 3TC, lamivudine; ABC, abacavir; bPI, boosted protease inhibitor; FTC, emtricitabine; IQR, interquartile range; NNRTI, non-nucleoside reverse transcriptase inhibitor; NRTI,
nucleoside reverse transcriptase inhibitor; TAF, tenofovir alafenamine; TDF, tenofovir; TI, treatment interruption.
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Table 1.

RESULTS

Table 2.

Factors Associated With Virological Replication (>50 Copies/mL) at Month 6 in the Overall Cohort (n = 399)
Univariate Analysis

Variables

Multivariate Analysis

No VR (n = 335)

VR (n = 64)

P Value

Age, mean (SD), y

44.5 (11.8)

41.6 (11.3)

.07

0.88 [0.63–1.22]

.44

Male

259 (77.3)

53 (82.8)

.41

1.36 [0.6–3.2]

.48

CD4 cells, mean (SD)

494 (256)

402 (250)

.009

0.97 [0.86–1.14]

.92

Log HIV-RNA, mean (SD), cp/mL

2.44 (1.23)

2.90 (1.37)

.008

1.61 [0.97–2.68]

.07

Third antiretroviral agent

aOR [95% CI]

P Value

.005

Dolutegravir-based

94 (28.1)

8 (12.5)

Ref.

Raltegravir-based

72 (21.5)

18 (28.1)

7.7 [2.4–25.2]

.0007

bPI-based

81 (24.2)

26 (40.6)

1.9 [0.6–6.0]

.29

NNRTI-based

88 (26.3)

12 (18.8)

3.4 [0.9–12.7]

.07

Treatment group
221 (66.0)

26 (40.6)

Ref.

Treatment-naïve

70 (20.9)

9 (14.1)

0.6 [0.1–4.2]

.63

Failed treatment

44 (13.1)

29 (41.3)

4.4 [1.4–14.0]

.012

211 (63.0)

20 (31.2)

Ref.

90%–95%

39 (11.6)

3 (4.7)

0.5 [0.1–2.1]

.35

80%–90%

47 (14.0)

5 (7.8)

0.8 [0.2–2.6]

.69

60%–80%

29 (8.7)

13 (20.3)

3.2 [1.0–10.0]

.043

9 (2.7)

23 (35.9)

5.9 [1.5–23.7]

.012

4.6 [1.3–16.9]

.02

Adherence class
>95%

<60%
Longest treatment interruption, log mean (SD), h

<.0001

1.63 (0.28)

2.06 (0.48)

<.0001

Abbreviations: aOR, adjusted odds ratio; bPI, boosted protease inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; VR, virological replication with HIV-RNA >50 cp/mL.

and 14/18 were subjected to nucleic acid amplification and
sequencing: 4 samples harbored INSTI conferring resistance to raltegravir (Q148H, N155H, Q148R, and Y143A). In
the NNRTI treatment group (Table 2), 12 PWH had HIVRNA replication (median [range] HIV-RNA, 854 [66-15 000]
copies/mL). In the bPI group (Table 2), 26 PWH had HIVRNA replication (median [range] HIV-RNA, 11 000 [59–
801 400] copies/mL). No data were available for resistance
testing in the bPI and NNRTI groups.
Adherence Pattern and HIV-RNA Relationships

Figure 1 displays the 6-month log10 HIV-RNA according to
the EDM-defined adherence pattern by antiretroviral regimen
among 399 PWH. As shown in Figure 2A, the surface plot for
dolutegravir-based triple therapy is flat, indicating a low level of
HIV-RNA replication regardless of the adherence pattern. None
of the models including adherence pattern parameters was significantly associated with 6-month HIV-RNA level (Figure 2A),
and the incremental HIV-RNA variance explained by the inclusion of adherence pattern variables was minimal (2%). In
contrast, the adherence patterns were significantly associated
with the level of virological replication above the detection
threshold for all older ARVs, with an incremental variance explained (R2) ranging from 14% (Figure 2D, model 2) to 54%
(Figure 2B, model 3). Model 3 had the highest HIV-RNA level
variance explained for the raltegravir group (Figure 2B) and the
bPI group (Figure 2D), suggesting that the influence of 1 adherence measure depends on the value of the other. Regarding
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the NNRTI group (Figure 2C), the longer treatment interruption (model 2) had the highest variance explained to predict
HIV-RNA level.
Predictors of HIV-RNA >50 Copies/mL

In the overall cohort, factors associated with virological detection (ie, probability of 6-month HIV-RNA >50 copies/mL) in
the univariate and multivariate analyses are shown in Table 2.
In the subgroup analyses based on average adherence, the
risk of virological detection was similar between all ARVs
among PWH with >95% adherence levels (Table 3) in the multivariate analysis. Among PWH with ≤95% adherence levels
(Table 3) and compared with those receiving a dolutegravirbased regimen, the risk of virological detection was significantly
and independently increased for the raltegravir-based regimen,
NNRTIs, and bPIs in the multivariate analysis.
DISCUSSION

In this cohort of PWH followed by EDM, the adherence
pattern to dolutegravir-based triple therapy was not a predictor of suppressed HIV-RNA. This picture contrasts with
the strong association between adherence pattern and HIVRNA level found for older regimens, including raltegravir-,
NNRTI-, and bPI-based ARV therapies. In addition,
dolutegravir therapy outperformed all other ARV strategies
in terms of virological suppression below the limit of detection among PWH in the lower adherence subgroup in the
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Switched treatment

<.0001

6-month HIV-RNA (in Log10)

4.74

Second-generation INSTI (DTG, n = 102)
First-generation INSTI (RAL, n = 90)
NNRTI (NVP, n = 70; EFV, n = 12; RPV, n = 18)

3.49

bPI (LPV/r, n = 54; ATV/r, n = 48; other, n = 3)

2.25

1412

40
295

60
Average adherence, %

62

80
100

13

Longest treatment interruption
in hours (Log10 scale)

Figure 1. Virological replication levels (log HIV-RNA) at 6 months by EDM adherence pattern according to antiretroviral regimen class (n = 399). Each circle symbol represents a PWH connected to the plane by a vertical needle. The length of the needle represents the HIV-RNA level of replication at 6 months in log cp/mL (z-axis). The horizontal
plane coordinates correspond to the EDM-defined adherence pattern during the 6-month period, with average adherence on the x-axis and the longest treatment interruption
in log10 hours on the y-axis. PWH with higher adherence are those in the bottom corner. Abbreviations: ATV/r, atazanavir/ritonavir; bPI, boosted protease inhibitor; DTG,
dolutegravir; EDM, electronic drug monitoring; EFV, efavirenz; LPV/r, lopinavir/ritonavir; NNRTI, non-nucleoside reverse transcriptase inhibitor; NVP, nevirapine; PWH, people
with HIV; RPV, rilpivirine.

multivariate analysis, adjusting for age, sex, CD4 cell count,
group (starting, switching, and failing), and baseline HIVRNA. No emerging mutation conferring resistance to INSTI
was detected in the dolutegravir group with detectable HIVRNA, in contrast with the raltegravir group. Taken together,
these results suggest that dolutegravir-based ARV therapies
are more forgiving to missed doses (either by average adherence or treatment interruptions) than the other investigated
ARVs regarding the risk of HIV-RNA replication. In addition, dolutegravir-based triple therapy is more forgiving to
missed doses than raltegravir-based triple therapy regarding
risk resistance.
Most of the previous studies in this area of research have
attempted to identify an adherence threshold required for virological suppression with the aim to challenge the >95% historical threshold. For example, Byrd et al. [8] reported that 75%
average adherence defined by pharmacy refill to INSTI-based
ARV therapy was required to suppress 90% of the treated patients. In this large cohort, first- and second-generation INSTIs
were pooled, although we found that the level of forgiveness
between dolutegravir and raltegravir strongly differed (as suggested in Figure 2A and B, respectively). Overall, the multivariate analysis of the risk of virological replication (n = 399)
(Table 1) is consistent with the >80% level of average adherence found in other studies [2,7,8] but reaffirms the importance

of treatment interruption length (adjusted odds ratio [aOR],
4.6; 95% CI, 1.3–16.9; P = .02) as an independent risk factor
[9,10,16].
Importantly, the use of dolutegravir was significantly and
independently associated with a lower risk of virological replication compared with other ARVs in the subgroup with lower
adherence. Although the 95% confidence intervals were large
due to the smaller sample size in this subgroup, this superiority is consistent with a network meta-analysis of 20 randomized trials in which a significantly higher proportion of naïve
PWH starting dolutegravir achieved virological suppression
at week 96 compared with protease inhibitors, efavirenz, and
cobicistat-boosted elvitegravir [17]. The pharmacokinetic forgiveness of dolutegravir-based regimens is supported by the
14-hour terminal elimination half-life of dolutegravir and its
duration of inhibitory effect (>2-fold higher than the IC90 for 72
hours after the last dose) [18]. In contrast, raltegravir, boosted
atazanavir, and boosted lopinavir have shorter terminal elimination half-lives: 10–12 hours [19], 8.3 hours, and 2.4 hours
[20], respectively. NNRTIs do have a long plasma half-life but
a relatively low genetic barrier to HIV-1 resistance. While prolonged plasma exposure improves pharmacokinetic forgiveness
[21], a period of functional monotherapy following NNRTIbased treatment interruption may select for low-frequency
resistant strains. Despite a high genetic barrier, dolutegravir
Forgiveness of Dolutegravir • ofid • 5
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1.00

β (SE)

Dolutegravir-based (n = 102)

6-month HIV-RNA (in Log10)

Model 1*
Adherence (+10%)

6.00

Model 2*
Longer TI
Model 3*
Adherence (+10%)
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monotherapy does promote INSTI-resistant strains [22], but
only after a long period of exposure. This scenario is unlikely
to occur when combined with other nucleosides in a fixed-dose
Table 3. Predictors of Virological Replication by Average Adherence
Subgroups in Multivariate Analysisa
Higher Adherence
(>95%)

Lower Adherence
(≤95%)

n = 211

n = 188

Third Antiretroviral Agent aOR [95% CI] P Value aOR [95% CI]
Dolutegravir-based

Ref.

P Value

Ref.

Raltegravir-based

3.7 [0.9–16.1]

.08

45.6 [4.5–462.1]

.001

bPI-based

0.6 [0.1–3.1]

.50

28.3 [3.4–239.4]

.002

NNRTI-based

3.4 [0.3–36.2]

.31

24.8 [2.7–228.4]

.005

Abbreviations: aOR, adjusted odds ratio; bPI, boosted protease inhibitor; NNRTI, nonnucleoside reverse transcriptase inhibitor.
a
Adjusting for age, sex, baseline CD4 cell count, baseline HIV-RNA, and treatment group
(failing, switching, or starting).

6 • ofid • Parienti et al

combination or when combined with nucleotides dosed once
daily whose anabolites have long intracellular half-lives.
There are several important limitations to this study.
Adherence was monitored by EDM, so we cannot prove that
the ARVs were ingested. The duration of the study, 6 months,
was short, and any virologic breakthrough before 6 months remained unnoticed. We compared nonrandomized groups of
PWH with different baseline characteristics. In particular, the
distribution of PWH who started treatment as a switch, treatment failure, or first therapy was different among treatment
groups (Table 1). The use of multivariate analysis adjusting
for important predictors of virological replication may have
contributed to attenuating this risk of bias, although residual
confounding may remain. The cohorts comparing different
treatment groups were not contemporaneously studied. We
investigated dolutegravir-based triple therapy. Therefore, our
results regarding dolutegravir should not be generalized to
dual therapies (with either rilpivirine or lamivudine) or to
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CONCLUSIONS

Our findings suggest that PWH treated with dolutegravir-based
combination therapy may be at lower risk of detectable virological replication than those treated with older regimens at
similar low to moderate adherence levels. While many factors
not evaluated in this work should influence the choice of ARV
therapy, including tolerance, pill burden, PWH preference, the
risk of drug–drug interaction, and costs, we recommend using
dolutegravir-based regimens for PWH who struggle to achieve
high levels of adherence or are at risk of treatment interruptions.
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